Fig. 5: Induction of apoptosis and viability after Entrectinib and Larotrectinib treatment in hES-MP cells expressing LMNA::TRKA and ETV6::TRKC fusion proteins. | Oncogenesis

Fig. 5: Induction of apoptosis and viability after Entrectinib and Larotrectinib treatment in hES-MP cells expressing LMNA::TRKA and ETV6::TRKC fusion proteins.

From: Generating in vitro models of NTRK-fusion mesenchymal neoplasia as tools for investigating kinase oncogenic activation and response to targeted therapy

Fig. 5

A hES-MP cells from clones 1 and 1.14, 3 and 3.3 and clone G2 before and after expression of Cre recombinase were exposed for 72 h to two doses of Entrectinib (20 and 200 nM) and Larotrectinib (200 and 1000 nM) and Annexin V was quantified as a measure of apoptosis. Annexin V intensity is represented as the ratio of the percentage of untreated cells. Error bars represent standard deviation from the mean of n ≥ 3 independent experiments. Unpaired t test *p < 0.05, **p < 0.01, ***p < 0.001, if not indicated the difference is not statistically significant. B Cells expressing the LMNA::TRKA protein (clone 1.14) and the corresponding parental cells (clone 1) were treated at increasing concentration of Entrectinib and Larotrectinib for 7 days continuously, before determination of cell viability. Results are presented as the mean of three independent experiments.

Back to article page